These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 31177657)
1. [An expert consensus for the adjustment of treatment strategies in patients with chronic hepatitis B treated with non-first-line nucleos(t)ide analogues]. ; Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):343-346. PubMed ID: 31177657 [TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis B virus infection - Dutch national guidelines. Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL; Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260 [TBL] [Abstract][Full Text] [Related]
3. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F; Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133 [TBL] [Abstract][Full Text] [Related]
4. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues? Papatheodoridis GV Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859 [TBL] [Abstract][Full Text] [Related]
5. Current developments in nucleoside/nucleotide analogues for hepatitis B. Lo AO; Wong GL Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):607-22. PubMed ID: 24787673 [TBL] [Abstract][Full Text] [Related]
6. HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs? Buti M Liver Int; 2014 Feb; 34 Suppl 1():108-11. PubMed ID: 24373086 [TBL] [Abstract][Full Text] [Related]
7. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues? Viganò M; Mangia G; Lampertico P Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088 [TBL] [Abstract][Full Text] [Related]
8. Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic hepatitis B patients. Chen L; Gan QR; Zhang DQ; Yao LF; Lin RS; Li Q; Lin MH; Yu DM; Zhang XX; Pan C Clin Microbiol Infect; 2016 Feb; 22(2):201-207. PubMed ID: 26493847 [TBL] [Abstract][Full Text] [Related]
9. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. Kang W; Park JY World J Gastroenterol; 2014 Jun; 20(23):7207-12. PubMed ID: 24966590 [TBL] [Abstract][Full Text] [Related]
10. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Buster EH; Schalm SW; Janssen HL Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869 [TBL] [Abstract][Full Text] [Related]
11. [Mechanism relevant to hepatocellular carcinoma occurrence after negative conversion of viral DNA in treatment of chronic hepatitis B patients with nucleos(t)ide drugs]. Gao TJ; Han GY; Lu FM Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):905-909. PubMed ID: 31941249 [TBL] [Abstract][Full Text] [Related]
12. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hongthanakorn C; Chotiyaputta W; Oberhelman K; Fontana RJ; Marrero JA; Licari T; Lok AS Hepatology; 2011 Jun; 53(6):1854-63. PubMed ID: 21618260 [TBL] [Abstract][Full Text] [Related]
13. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241 [TBL] [Abstract][Full Text] [Related]
14. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763 [TBL] [Abstract][Full Text] [Related]
15. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492 [TBL] [Abstract][Full Text] [Related]
16. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. Wei L; Kao JH Curr Med Res Opin; 2017 Mar; 33(3):495-504. PubMed ID: 27882776 [TBL] [Abstract][Full Text] [Related]
17. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention]. Han C; Dou XG Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):293-296. PubMed ID: 33979951 [TBL] [Abstract][Full Text] [Related]
18. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Kao JH Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087 [TBL] [Abstract][Full Text] [Related]
19. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs. Li T; Liu F; Zhang L; Ye Q; Fan X; Xue Y; Wang L Saudi J Gastroenterol; 2018; 24(1):30-36. PubMed ID: 29451182 [TBL] [Abstract][Full Text] [Related]
20. Systematic review: combination therapies for treatment-naïve chronic hepatitis B. Kumar M; Sarin SK Aliment Pharmacol Ther; 2008 Jun; 27(12):1187-209. PubMed ID: 18373730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]